

DRAFT LETTER

To Senator Migden; Assembly persons Leno and Huffman

RE: SB 1096 (Calderon) – OPPOSE

Dear

The Marin County Board of Supervisors opposes SB 1096, Senator Calderon's bill regarding pharmacists' distribution of marketing information, and urges your opposition to the bill.

SB 1096 is counter to the State and federal trends aimed at protecting confidential information and in allowing consumers to proactively "opt out" of proposed uses of their personal information. The bill would encourage pharmacists to become a marketing arm of drug manufacturers and others and could lead to patient confusion over their physician's prescribed course of treatment.

The Marin County Board of Supervisors has a longstanding commitment to ensuring the privacy rights of individuals, including the ability to maintain the confidentiality of personal records. The need to protect individual privacy rights becomes more and more important, as we learn of more and more breaches and inappropriate uses of protected personal data.

We urge your opposition to SB 1096.

AMENDED IN SENATE MAY 23, 2008

AMENDED IN SENATE MAY 8, 2008

AMENDED IN SENATE APRIL 14, 2008

SENATE BILL

No. 1096

Introduced by Senator Calderon

January 14, 2008

An act to amend Section 56.10 of the Civil Code, relating to medical information.

LEGISLATIVE COUNSEL'S DIGEST

SB 1096, as amended, Calderon. Medical information.

The Confidentiality of Medical Information Act prohibits a provider of health care, a health care service plan, contractor, or corporation and its subsidiaries and affiliates from intentionally sharing, selling, using for marketing, or otherwise using any medical information, as defined, for any purpose not necessary to provide health care services to a patient, except as expressly authorized by the patient, enrollee, or subscriber, as specified, or as otherwise required or authorized by law. Violations of these provisions are subject to a civil action for compensatory and punitive damages, and, if a violation results in economic loss or personal injury to a patient, it is punishable as a misdemeanor.

This bill would, under those provisions, allow a pharmacy to mail specified written communications to a patient, without the patient's authorization under specified conditions. Those conditions include, among other things, that the written communication be written in the same language as the prescription label, that it instruct the patient when to contact the health care professional, that it shall pertain only to the prescribed course of medical treatment, that it may not mention any

other pharmaceutical products, that it shall be limited to specified diseases, that further written communication may not be provided under certain circumstances, that a copy of each version shall be submitted to the federal Food and Drug Administration, ~~and~~ that it shall include specified disclosures regarding whether the pharmacy receives direct or indirect remuneration for making that written communication, *and that the patient shall receive an opportunity to opt out of the written communication.*

Vote: majority. Appropriation: no. Fiscal committee: no.
State-mandated local program: no.

The people of the State of California do enact as follows:

1 SECTION 1. Section 56.10 of the Civil Code is amended to
2 read:

3 56.10. (a) No provider of health care, health care service plan,
4 or contractor shall disclose medical information regarding a patient
5 of the provider of health care or an enrollee or subscriber of a
6 health care service plan without first obtaining an authorization,
7 except as provided in subdivision (b), (c), or (d).

8 (b) A provider of health care, a health care service plan, or a
9 contractor shall disclose medical information if the disclosure is
10 compelled by any of the following:

11 (1) By a court pursuant to an order of that court.

12 (2) By a board, commission, or administrative agency for
13 purposes of adjudication pursuant to its lawful authority.

14 (3) By a party to a proceeding before a court or administrative
15 agency pursuant to a subpoena, subpoena duces tecum, notice to
16 appear served pursuant to Section 1987 of the Code of Civil
17 Procedure, or any provision authorizing discovery in a proceeding
18 before a court or administrative agency.

19 (4) By a board, commission, or administrative agency pursuant
20 to an investigative subpoena issued under Article 2 (commencing
21 with Section 11180) of Chapter 2 of Part 1 of Division 3 of Title
22 2 of the Government Code.

23 (5) By an arbitrator or arbitration panel, when arbitration is
24 lawfully requested by either party, pursuant to a subpoena duces
25 tecum issued under Section 1282.6 of the Code of Civil Procedure,
26 or any other provision authorizing discovery in a proceeding before
27 an arbitrator or arbitration panel.

1 (6) By a search warrant lawfully issued to a governmental law
2 enforcement agency.

3 (7) By the patient or the patient's representative pursuant to
4 Chapter 1 (commencing with Section 123100) of Part 1 of Division
5 106 of the Health and Safety Code.

6 (8) By a coroner, when requested in the course of an
7 investigation by the coroner's office for the purpose of identifying
8 the decedent or locating next of kin, or when investigating deaths
9 that may involve public health concerns, organ or tissue donation,
10 child abuse, elder abuse, suicides, poisonings, accidents, sudden
11 infant deaths, suspicious deaths, unknown deaths, or criminal
12 deaths, or when otherwise authorized by the decedent's
13 representative. Medical information requested by the coroner under
14 this paragraph shall be limited to information regarding the patient
15 who is the decedent and who is the subject of the investigation and
16 shall be disclosed to the coroner without delay upon request.

17 (9) When otherwise specifically required by law.

18 (c) A provider of health care or a health care service plan may
19 disclose medical information as follows:

20 (1) The information may be disclosed to providers of health
21 care, health care service plans, contractors, or other health care
22 professionals or facilities for purposes of diagnosis or treatment
23 of the patient. This includes, in an emergency situation, the
24 communication of patient information by radio transmission or
25 other means between emergency medical personnel at the scene
26 of an emergency, or in an emergency medical transport vehicle,
27 and emergency medical personnel at a health facility licensed
28 pursuant to Chapter 2 (commencing with Section 1250) of Division
29 2 of the Health and Safety Code.

30 (2) The information may be disclosed to an insurer, employer,
31 health care service plan, hospital service plan, employee benefit
32 plan, governmental authority, contractor, or any other person or
33 entity responsible for paying for health care services rendered to
34 the patient, to the extent necessary to allow responsibility for
35 payment to be determined and payment to be made. If (A) the
36 patient is, by reason of a comatose or other disabling medical
37 condition, unable to consent to the disclosure of medical
38 information and (B) no other arrangements have been made to pay
39 for the health care services being rendered to the patient, the
40 information may be disclosed to a governmental authority to the

1 extent necessary to determine the patient's eligibility for, and to
2 obtain, payment under a governmental program for health care
3 services provided to the patient. The information may also be
4 disclosed to another provider of health care or health care service
5 plan as necessary to assist the other provider or health care service
6 plan in obtaining payment for health care services rendered by that
7 provider of health care or health care service plan to the patient.

8 (3) The information may be disclosed to a person or entity that
9 provides billing, claims management, medical data processing, or
10 other administrative services for providers of health care or health
11 care service plans or for any of the persons or entities specified in
12 paragraph (2). However, no information so disclosed shall be
13 further disclosed by the recipient in any way that would violate
14 this part.

15 (4) The information may be disclosed to organized committees
16 and agents of professional societies or of medical staffs of licensed
17 hospitals, licensed health care service plans, professional standards
18 review organizations, independent medical review organizations
19 and their selected reviewers, utilization and quality control peer
20 review organizations as established by Congress in Public Law
21 97-248 in 1982, contractors, or persons or organizations insuring,
22 responsible for, or defending professional liability that a provider
23 may incur, if the committees, agents, health care service plans,
24 organizations, reviewers, contractors, or persons are engaged in
25 reviewing the competence or qualifications of health care
26 professionals or in reviewing health care services with respect to
27 medical necessity, level of care, quality of care, or justification of
28 charges.

29 (5) The information in the possession of a provider of health
30 care or health care service plan may be reviewed by a private or
31 public body responsible for licensing or accrediting the provider
32 of health care or health care service plan. However, no
33 patient-identifying medical information may be removed from the
34 premises except as expressly permitted or required elsewhere by
35 law, nor shall that information be further disclosed by the recipient
36 in any way that would violate this part.

37 (6) The information may be disclosed to the county coroner in
38 the course of an investigation by the coroner's office when
39 requested for all purposes not included in paragraph (8) of
40 subdivision (b).

1 (7) The information may be disclosed to public agencies, clinical
2 investigators, including investigators conducting epidemiologic
3 studies, health care research organizations, and accredited public
4 or private nonprofit educational or health care institutions for bona
5 fide research purposes. However, no information so disclosed shall
6 be further disclosed by the recipient in any way that would disclose
7 the identity of a patient or violate this part.

8 (8) A provider of health care or health care service plan that has
9 created medical information as a result of employment-related
10 health care services to an employee conducted at the specific prior
11 written request and expense of the employer may disclose to the
12 employee's employer that part of the information that:

13 (A) Is relevant in a lawsuit, arbitration, grievance, or other claim
14 or challenge to which the employer and the employee are parties
15 and in which the patient has placed in issue his or her medical
16 history, mental or physical condition, or treatment, provided that
17 information may only be used or disclosed in connection with that
18 proceeding.

19 (B) Describes functional limitations of the patient that may
20 entitle the patient to leave from work for medical reasons or limit
21 the patient's fitness to perform his or her present employment,
22 provided that no statement of medical cause is included in the
23 information disclosed.

24 (9) Unless the provider of health care or health care service plan
25 is notified in writing of an agreement by the sponsor, insurer, or
26 administrator to the contrary, the information may be disclosed to
27 a sponsor, insurer, or administrator of a group or individual insured
28 or uninsured plan or policy that the patient seeks coverage by or
29 benefits from, if the information was created by the provider of
30 health care or health care service plan as the result of services
31 conducted at the specific prior written request and expense of the
32 sponsor, insurer, or administrator for the purpose of evaluating the
33 application for coverage or benefits.

34 (10) The information may be disclosed to a health care service
35 plan by providers of health care that contract with the health care
36 service plan and may be transferred among providers of health
37 care that contract with the health care service plan, for the purpose
38 of administering the health care service plan. Medical information
39 may not otherwise be disclosed by a health care service plan except
40 in accordance with the provisions of this part.

1 (11) Nothing in this part shall prevent the disclosure by a
2 provider of health care or a health care service plan to an insurance
3 institution, agent, or support organization, subject to Article 6.6
4 (commencing with Section 791) of Part 2 of Division 1 of the
5 Insurance Code, of medical information if the insurance institution,
6 agent, or support organization has complied with all requirements
7 for obtaining the information pursuant to Article 6.6 (commencing
8 with Section 791) of Part 2 of Division 1 of the Insurance Code.

9 (12) The information relevant to the patient's condition and care
10 and treatment provided may be disclosed to a probate court
11 investigator in the course of any investigation required or
12 authorized in a conservatorship proceeding under the
13 Guardianship-Conservatorship Law as defined in Section 1400 of
14 the Probate Code, or to a probate court investigator, probation
15 officer, or domestic relations investigator engaged in determining
16 the need for an initial guardianship or continuation of an existent
17 guardianship.

18 (13) The information may be disclosed to an organ procurement
19 organization or a tissue bank processing the tissue of a decedent
20 for transplantation into the body of another person, but only with
21 respect to the donating decedent, for the purpose of aiding the
22 transplant. For the purpose of this paragraph, the terms "tissue
23 bank" and "tissue" have the same meaning as defined in Section
24 1635 of the Health and Safety Code.

25 (14) The information may be disclosed when the disclosure is
26 otherwise specifically authorized by law, including, but not limited
27 to, the voluntary reporting, either directly or indirectly, to the
28 federal Food and Drug Administration of adverse events related
29 to drug products or medical device problems.

30 (15) Basic information, including the patient's name, city of
31 residence, age, sex, and general condition, may be disclosed to a
32 state or federally recognized disaster relief organization for the
33 purpose of responding to disaster welfare inquiries.

34 (16) The information may be disclosed to a third party for
35 purposes of encoding, encrypting, or otherwise anonymizing data.
36 However, no information so disclosed shall be further disclosed
37 by the recipient in any way that would violate this part, including
38 the unauthorized manipulation of coded or encrypted medical
39 information that reveals individually identifiable medical
40 information.

1 (17) For purposes of disease management programs and services
2 as defined in Section 1399.901 of the Health and Safety Code,
3 information may be disclosed as follows: (A) to an entity
4 contracting with a health care service plan or the health care service
5 plan's contractors to monitor or administer care of enrollees for a
6 covered benefit, if the disease management services and care are
7 authorized by a treating physician, or (B) to a disease management
8 organization, as defined in Section 1399.900 of the Health and
9 Safety Code, that complies fully with the physician authorization
10 requirements of Section 1399.902 of the Health and Safety Code,
11 if the health care service plan or its contractor provides or has
12 provided a description of the disease management services to a
13 treating physician or to the health care service plan's or contractor's
14 network of physicians. Nothing in this paragraph shall be construed
15 to require physician authorization for the care or treatment of the
16 adherents of a well-recognized church or religious denomination
17 who depend solely upon prayer or spiritual means for healing in
18 the practice of the religion of that church or denomination.

19 (18) The information may be disclosed, as permitted by state
20 and federal law or regulation, to a local health department for the
21 purpose of preventing or controlling disease, injury, or disability,
22 including, but not limited to, the reporting of disease, injury, vital
23 events, including, but not limited to, birth or death, and the conduct
24 of public health surveillance, public health investigations, and
25 public health interventions, as authorized or required by state or
26 federal law or regulation.

27 (19) The information may be disclosed, consistent with
28 applicable law and standards of ethical conduct, by a
29 psychotherapist, as defined in Section 1010 of the Evidence Code,
30 if the psychotherapist, in good faith, believes the disclosure is
31 necessary to prevent or lessen a serious and imminent threat to the
32 health or safety of a reasonably foreseeable victim or victims, and
33 the disclosure is made to a person or persons reasonably able to
34 prevent or lessen the threat, including the target of the threat.

35 (20) The information may be disclosed as described in Section
36 56.103.

37 (d) Except to the extent expressly authorized by the patient or
38 enrollee or subscriber or as provided by subdivisions (b) and (c),
39 no provider of health care, health care service plan, contractor, or
40 corporation and its subsidiaries and affiliates shall intentionally

1 share, sell, use for marketing, or otherwise use any medical
2 information for any purpose not necessary to provide health care
3 services to the patient. For purposes of this section, a written
4 communication mailed to a patient by a pharmacy shall be deemed
5 to be necessary to provide health care services to the patient and
6 shall not require prior authorization, if all of the following
7 conditions are met:

8 (1) The written communication encourages the patient to adhere
9 to the prescribed course of medical treatment as prescribed by a
10 licensed health care professional and may include information
11 about that particular pharmaceutical drug as authorized in this
12 section.

13 (2) The communication is written in the same language as the
14 prescription label produced by the pharmacy when the medication
15 was dispensed.

16 (3) The written communication instructs the patient to contact
17 the prescribing or dispensing health care professional if:

18 (A) The patient has questions about the medication.

19 (B) The patient is having difficulty adhering to the medication
20 due to adverse effects, dosing requirements, or other causes.

21 (4) The written communication pertains only to the prescribed
22 course of medical treatment, and does not describe or mention any
23 other pharmaceutical products. The written communication shall
24 be limited to the following diseases:

25 (A) Diabetes.

26 (B) Osteoporosis.

27 (C) Asthma.

28 (D) Chronic obstructive pulmonary disease.

29 (E) Cancer.

30 (F) Gastric disorder.

31 (G) Hypertension.

32 (H) Cardiovascular disease.

33 (I) Thyroid disorder.

34 (J) Organ transplantation.

35 (K) Chronic eye disorder.

36 (L) Rheumatoid arthritis and osteoarthritis.

37 (M) Renal disorders.

38 (N) Parkinson's disease.

39 (O) Seizures.

40 (P) Multiple sclerosis.

(Q) Depression.

(R) Schizophrenia.

(S) Bipolar disorder.

(T) Anxiety disorders.

(U) Attention deficit disorder.

(5) Further written communication shall not be provided if there are no refills remaining on the prescribed course of therapy and there are no doses remaining on the final prescribed refill, or the pharmacy has been notified by a health care provider that a prescribed course of therapy has been discontinued or substituted with a different drug.

(6) All product-related information in the written communication shall be consistent with the current federal Food and Drug Administration (FDA) approved product package insert, and provide fair and balanced information regarding the product's benefits and risks in accordance with the FDA requirements and policies.

(7) A copy of each written communication version shall be submitted to the FDA Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising and Communications, prior to program implementation.

(8) Evidence-based or consensus-based practice guidelines shall be the basis of any information that is provided to patients in order to improve their overall health, prevent clinical exacerbations or complications, or promote patient self-management strategies.

(9) All personally identifiable medical information collected, used, and disclosed pursuant to this subdivision shall be confidential and shall be used solely to deliver the written communication to the patient. Access to the information shall be limited to authorized persons. Any entity that receives the information pursuant to this subdivision shall comply with existing requirements, including Sections 56.101 and 1798.84, concerning confidentiality and security of information. The pharmacy must have a written agreement with any entity that receives the information. The written agreement shall require the entity to maintain the confidentiality of the information it receives from the pharmacy and prohibit the entity from disclosing or using the information for any purpose other than to deliver to the patient the written communication that is the subject of the written agreement.

1 (10) If the written communication is paid for, in whole or in
2 part, by a manufacturer, distributor, or provider of a health care
3 product or service, the written communication shall disclose
4 whether the pharmacy receives direct or indirect remuneration,
5 including, but not limited to, gifts, fees, payments, subsidies, or
6 other economic benefits from a third party for making the written
7 communication and shall disclose, in a clear and conspicuous
8 location, the source of any sponsorship in a typeface no smaller
9 than 14-point type.

10 ~~(11) The communication contains instructions in a typeface no~~
11 ~~smaller than 14-point type describing how the patient may opt out~~
12 ~~of future communications by, for example, calling a toll-free~~
13 ~~number or visiting a Web site, and no further sponsored message~~
14 ~~is made to the individual after 30 calendar days from the date the~~
15 ~~individual makes the opt out request.~~

16 *(11) A pharmacy offers the patient, at the time the patient picks*
17 *up his or her initial prescription, an opportunity to opt out of*
18 *receiving a written communication from a pharmacy. If the patient*
19 *opts out, then no sponsored message shall be made to the patient.*
20 *If, at the time the patient picks up his or her initial prescription,*
21 *the patient does not opt out, then the written communication shall*
22 *contain instructions in a typeface no smaller than 14-point type*
23 *describing how the patient may opt out of future communications*
24 *by, for example, calling a toll-free telephone number or visiting*
25 *an Internet Web site, and no further sponsored message shall be*
26 *made to the patient after 30 calendar days from the date the*
27 *individual makes the opt out request.*

28 (e) Except to the extent expressly authorized by the patient or
29 enrollee or subscriber or as provided by subdivisions (b) and (c),
30 no contractor or corporation and its subsidiaries and affiliates shall
31 further disclose medical information regarding a patient of the
32 provider of health care or an enrollee or subscriber of a health care
33 service plan or insurer or self-insured employer received under
34 this section to any person or entity that is not engaged in providing
35 direct health care services to the patient or his or her provider of
36 health care or health care service plan or insurer or self-insured
37 employer.